For research teamsFind studies
Back to all studies
CompletedNCT03238326

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

This study is completed. It focuses on schizophrenia and currently lists study information in France, Italy, Mexico, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, and the United States.

SchizophreniaOtherFrom 13 Years to 17 Years
In plain English

Key information made simple

This study exists to understand how a medication treatment holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted. For people living with Schizophrenia, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a lab, with sites including Clinical Research Site #101 in Dothan, Clinical Research Site #128 in Anaheim, and Clinical Research Site #105 in Culver City. Participation appears to involve study activities and check-ins designed to see how this approach works in practice. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include active substance or alcohol problems that could affect the results and other treatments that could interfere with the study. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT03238326. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may help improve understanding of your condition.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in France.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Main activity
medication or study treatment
Time commitment
long follow-up or multiple visits
Study phase
Not available
Enrollment
Not available
Recruitment status
Completed
Source
Official registry link
FAQ

Questions about this study

What is Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company. Otsuka is a pharmaceutical company within the Otsuka group, with work across prescription medicines and healthcare products. The sponsor is based in Japan. Sponsor website: https://www.otsuka.co.jp/en/. You can verify the sponsor and study responsibility in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Related studies

Other studies you may want to explore next

Safety and Tolerability of Open-Label. — Schizophrenia Clinical Trial | HopeStage